Trixeo Aerosphere approved in the EU for COPD
14 December 2020 07:00 GMT Trixeo Aerosphere approved in the EU for maintenance treatment of COPD Fourth major approval for AstraZenecaÕs triple-combination therapywhich is marketed as Breztri Aerosphere in the US, China and Japan AstraZenecaÕs Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been approved in the European Union (EU) for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-